Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Current Deferred Revenue (2024 - 2026)

Exagen filings provide 3 years of Current Deferred Revenue readings, the most recent being $700000.0 for Q1 2026.

  • On a quarterly basis, Current Deferred Revenue fell 22.22% to $700000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $700000.0, a 22.22% decrease, with the full-year FY2025 number at $700000.0, down 4.5% from a year prior.
  • Current Deferred Revenue hit $700000.0 in Q1 2026 for Exagen, roughly flat from $700000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.0 million in Q2 2025 to a low of $600000.0 in Q3 2025.
  • Median Current Deferred Revenue over the past 3 years was $716500.0 (2024), compared with a mean of $772166.7.
  • Biggest five-year swings in Current Deferred Revenue: decreased 4.5% in 2025 and later dropped 22.22% in 2026.
  • Exagen's Current Deferred Revenue stood at $733000.0 in 2024, then dropped by 4.5% to $700000.0 in 2025, then changed by 0.0% to $700000.0 in 2026.
  • The last three reported values for Current Deferred Revenue were $700000.0 (Q1 2026), $700000.0 (Q4 2025), and $600000.0 (Q3 2025) per Business Quant data.